Dublin, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Point-of-Care Coagulation Testing Market 2016-2020" report to their offering. The global point-of-care coagulation testing market to grow at a CAGR of 6.53% during the period 2016-2020.
Global Point-Of-Care Coagulation Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. A 360-degree view of the market, based on products, application, and technology segments.
Coagulation testing measures the ability of blood to form a clot. Clotting is the process of the blood converting from a liquid into a gel form. Coagulation tests are carried out to detect clotting disorders such as hemorrhage and thrombosis. Many types of coagulation tests exist, including complete blood count, factor V assay, fibrinogen level, PT, platelet count, TT, and bleeding time.
According to the report, advances in technology will be a key driver for market growth. Vendors are continually investing in R&D to develop products with advanced technology. POCT technology too has evolved from traditional laboratories in terms of quality of tests offered and cost-effectiveness. For instance, the molecular diagnosis is a complex form of testing, and the development of POCT devices for molecular diagnostics is on the rise. In addition, sensor technologies in the medical field have made the rapid analysis of blood samples possible for many critical care assays, including electrolytes, blood gases, and hematology. Biosensors are today being used for toxicology and drug screenings, measurement of blood cells, coagulation disorders, and checking for vitamin K deficiency. Further, the report states that high cost of coagulation analyzers will be a challenge for the market. POC tests are usually associated with high cost, both in terms of consumables used and TAT. It is difficult to determine the cost-effectiveness of POCT because the cost factor cannot be calculated on the basis of spending on the tests alone. Down savings such as decreased LOS, readmission rates, and improvements in patient outcomes are major factors that fall within the purview of the cost-effectiveness of a test. Key vendors
- Abbott Laboratories
- Alere Inc.
- F. Hoffmann-La Roche AG
- Siemens AG
Other prominent vendors
- Accriva Diagnostics
- CoaquSense
- Diagon
- Helena Point of Care
- HemoSonics
- iLine Microsystems
- Medtronic
- Micropoint Bioscience
- Sysmex
Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Segmentation by product Part 07: Market segmentation by application Part 08: Market segmentation by technology Part 09: Market segmentation by end-user Part 10: Geographical segmentation Part 11: Market drivers Part 12: Impact of drivers Part 13: Market challenges Part 14: Impact of drivers and challenges Part 15: Market trends Part 16: Vendor landscape Part 17: Appendix For more information about this report visit http://www.researchandmarkets.com/research/7r9h2s/global
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Point-of-Care Diagnostics, Coagulation and Hemostasis Testing
